M

Marker Therapeutics
D

MRKR

1.52000
USD
-0.11
(-6.75%)
مغلق
حجم التداول
335
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
16,277,688
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AXON
    -28.72
    (-5.30%)
    513.31 USD
    C
    CRIS
    -0.03400
    (-1.09%)
    3.07600 USD
    G
    GH
    -4.510
    (-9.51%)
    42.910 USD
    I
    IONS
    -0.365
    (-1.12%)
    32.310 USD
    M
    MGTX
    0.45000
    (6.58%)
    7.29000 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    X
    XBIT
    -0.11600
    (-3.73%)
    2.99000 USD
    R
    RDUS
    0.110
    (0.84%)
    13.200 USD
    المزيد
الأخبار
المقالات

العنوان: Marker Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.